免疫检查点抑制剂相关免疫不良事件的可疑合并用药药物警戒研究
本研究基于WHO VigiBase药物警戒数据库截至2024年1月的免疫检查点抑制剂(ICI)个案安全报告,分析合并用药与免疫相关不良事件(irAE)报告风险的关联。共纳入169,753份ICI相关报告,发现质子泵抑制剂、非甾体抗炎药、他汀类、酮康唑、DPP-4抑制剂等多种合并用药与特定irAE报告风险升高相关,部分关联提示协同毒性。
要点
- PPI与肾炎报告风险升高相关(ROR=29.62,95%CI 18.61-47.14)。
- 他汀类与肌炎报告风险升高相关(ROR=9.41,95%CI 3.50-25.30)。
- 布洛芬与肾炎、流感疫苗与心肌炎的关联在ICI人群中提示协同毒性。
核心结论
- 多种非抗癌合并用药与ICI治疗患者特定irAE的报告风险升高相关,部分关联可能为协同毒性,需进一步研究。
研究设计与样本
- 药物警戒研究,提取WHO VigiBase数据库中截至2024年1月所有涉及ICI的个案安全报告(ICSRs)。
- 共纳入169,753份ICI相关ICSRs,记录314,366条合并用药,其中8,122条被识别为「可疑或相互作用」药物。
主要发现
- 质子泵抑制剂(PPI)与肾炎报告风险升高相关(ROR=29.62,95%CI 18.61-47.14),非甾体抗炎药(NSAIDs)与肾炎相关(ROR=10.47,95%CI 4.15-26.41)。
- 他汀类与肌炎相关(ROR=9.41,95%CI 3.50-25.30),酮康唑与肝炎相关(ROR=20.49,95%CI 1.53-274.17),DPP-4抑制剂与自身免疫性大疱病相关(ROR=46.42,95%CI 11.71-184.05)。
- PPI(ROR=8.61,95%CI 3.48-21.26)、磺胺甲噁唑(ROR=31.31,95%CI 13.32-73.61)、克拉维酸(ROR=18.12,95%CI 4.77-68.89)、别嘌醇(ROR=57.11,95%CI 11.27-289.39)、左乙拉西坦(ROR=14.91,95%CI 2.15-103.64)与严重皮肤不良反应相关。
- 补充分析显示,布洛芬与肾炎的关联在ICI人群中ROR=27.82,非ICI人群ROR=3.56,RORratio=7.81(95%CI 1.23-49.50);流感疫苗与心肌炎的关联在ICI人群中ROR=22.74,非ICI人群ROR=0.66,RORratio=34.45(95%CI 1.66-723.24),提示协同毒性。
临床怎么用
- 临床对接受ICI治疗的患者应关注合并用药,尤其是PPI、NSAIDs、他汀类、酮康唑、DPP-4抑制剂、磺胺甲噁唑、克拉维酸、别嘌醇、左乙拉西坦等可能增加特定irAE报告风险的药物。
- 对上述合并用药相关irAE保持警惕,及时识别和处理,必要时考虑调整合并用药方案。
局限性
- 本研究为药物警戒数据库分析,报告风险比不能直接推断因果关系。
- 部分关联的95%置信区间较宽,如酮康唑与肝炎、流感疫苗与心肌炎的RORratio,结果需谨慎解读。
- 研究未报告合并用药的剂量、疗程及患者个体因素对关联的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune-checkpoint inhibitors (ICI) have revolutionized cancer treatment but are responsible for various immune-related adverse events (irAE). The impact of non-anticancer medications (comedications) on irAE occurrence remains largely unexplored. The objective of this study was to assess comedications associated with an increased reporting of irAE with ICIs. In this pharmacovigilance study, all individual case safety reports (ICSRs) involving ICIs reported in the World Health Organization international pharmacovigilance database Vigibase up to January 2024 were extracted. All suspect or interacting comedications were analyzed individually and as drug classes using Anatomical Therapeutic Chemical classification level 4. The primary outcome was the reporting odds ratio (ROR) of irAE in patients who received both an ICI and the comedication of interest, compared with ICI-treated patients who did not receive that comedication. Among 169,753 ICSRs involving an ICI, a total of 314,366 comedications were recorded, with 8,122 identified as "suspect or interacting." Analysis shows an increased reporting of nephritis with proton pump inhibitors (PPI) (ROR = 29.62 [95% CI = 18.61-47.14]) and with non-steroidal anti-inflammatory drugs (ROR = 10.47 [95% CI = 4.15-26.41]), myositis with statins (ROR = 9.41 [95% CI = 3.50-25.30]), ketoconazole with hepatitis (ROR = 20.49 [95% CI = 1.53-274.17]) and autoimmune bullous disease with dipeptyl-peptidase-4 inhibitors (ROR = 46.42 [95% CI = 11.71-184.05]), among others. Various drugs, including PPI (ROR = 8.61 [95% CI = 3.48-21.26]), some anti-infectives (sulfamethoxazole, ROR = 31.31 [95% CI = 13.32-73.61], clavulanic acid, ROR = 18.12 [95% CI = 4.77-68.89]), allopurinol (ROR = 57.11 [95% CI = 11.27-289.39]) or levetiracetam (ROR = 14.91 [95% CI = 2.15-103.64]) were associated with serious cutaneous adverse reactions. Complementary analysis showed higher ROR in the ICI population versus without ICI for the association of nephritis with ibuprofen (RORICI = 27.82 vs. RORVigiBaseWithoutICI = 3.56, RORratio = 7.81 [95% CI = 1.23-49.50]) and myocarditis with influenza vaccine (RORICI = 22.74 vs. RORVigiBaseWithoutICI = 0.66, RORratio = 34.45 [95% CI = 1.66-723.24]), suggesting a synergistic toxicity. This study identified multiple comedications associated with an increased reporting of specific irAE. Some of them might be synergistic warranting further investigation.
引用
- Laurent L, Abbar B, Bihan K, et al. Comedications Associated with Immune-Related Adverse Events from Immune-Checkpoint Inhibitors. Clin Pharmacol Ther. 2025. PMID: 40521636. doi:10.1002/cpt.3721
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。